Crossmark

Establishment and validation of a prediction model for the first recurrence of Budd–Chiari syndrome after endovascular treatment: a large sample size, single-center retrospective study

Crossref DOI link: https://doi.org/10.1007/s12072-022-10464-y

Published Online: 2022-12-26

Published Print: 2023-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Zhongkai

Wang, Ziwei

Zhang, Zhiyuan

Li, Jiandong

Pan, Zhiyang

Liu, Ang

Lu, Jian

Guo, Jinhe

Zu, Maoheng

Xu, Hao
License Information

Text and Data Mining valid from 2022-12-26

Version of Record valid from 2022-12-26
More Information

Article History

Received: 18 September 2022

Accepted: 24 November 2022

First Online: 26 December 2022

Declarations

:

: The authors Zhongkai Wang, Ziwei Wang, Zhiyuan Zhang, Jiandong Li, Zhiyang Pan, Ang Liu, Jian Lu, Jinhe Guo, Maoheng Zu, and Hao Xu declare that there is no conflict of interest.

: We conducted a single-center, retrospective cohort study approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (Jiangsu, China; XYFY2019-KL173-01). All procedures were performed according to the Helsinki Declaration of 1975.

: All enrolled patients gave written informed consent.

Document is current

Any future updates will be listed below